# CF PharmTech, Inc.
# 長風藥業股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2652)**

## VOLUNTARY ANNOUNCEMENT
## INCLUSION OF THE COMPANY IN THE LIST OF ELIGIBLE SECURITIES FOR THE SHANGHAI-HONG KONG STOCK CONNECT AND SHENZHEN-HONG KONG STOCK CONNECT

This announcement is made by CF PharmTech, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, pursuant to the notices on the adjustment to the list of eligible securities for the Hong Kong Stock Connect published by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, the H shares of the Company (the "**H Shares**") have been officially included in the list of eligible securities for the Hong Kong Stock Connect under both the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, with such changes taking effect from March 9, 2026.

Starting from the effective date, eligible mainland Chinese investors who meet the admission criteria for the Hong Kong Stock Connect will be able to trade the H Shares of the Company listed on The Stock Exchange of Hong Kong Limited through the Hong Kong Stock Connect mechanism under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.

The Board expects that such inclusion will help expand the shareholder base of the Company and increase the trading liquidity of the H Shares.

## ABOUT THE COMPANY

As a global innovator in inhalation drug delivery technology, CF PharmTech, Inc. is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is not only a specialist in the development of complex inhalation formulations with high barriers to entry, but also a platform-based innovative pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, global regulatory filing and commercialization.

Leveraging its fully self-developed, globally integrated end-to-end capabilities — from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to siRNA nucleic acid delivery platforms — the Company is systematically advancing its proprietary innovative pipeline for the markets in China, the United States and Europe. Its therapeutic areas encompass respiratory diseases (including asthma, chronic obstructive pulmonary disease and bronchiectasis) and nasal diseases (including allergic rhinitis and chronic rhinosinusitis), with strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders, as the Company advances precision drug delivery via the nose-to-brain pathway.

The Company has established an extensive multi-dimensional commercialization network in China and, through its globally compliant manufacturing systems and deepening international presence, is steadily advancing towards its goal of becoming a global innovative pharmaceutical enterprise.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board
**CF PharmTech, Inc.**
**長風藥業股份有限公司**
**Dr. LIANG Bill Wenqing**
*Chairperson, Executive Director and Chief Executive Officer*

Hong Kong, March 8, 2026

*As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu as executive Directors, Mr. CHEN Penghui, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.*